©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Retinoic Acid Down-regulation of Fibronectin and Retinoic Acid Receptor Proteins in NIH-3T3 Cells
BLOCK OF THIS RESPONSE BY ras TRANSFORMATION (*)

(Received for publication, August 30, 1995; and in revised form, November 14, 1995)

Giorgio Scita Nadine Darwiche Eileen Greenwald Miriam Rosenberg Katerina Politi Luigi M. De Luca (§)

From the Laboratory of Cellular Carcinogenesis and Tumor Promotion, NCI, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

All-trans-retinoic acid (RA) markedly reduced the level of intracellular fibronectin (FN) in a time- and concentration-dependent fashion in NIH-3T3 cells, but not in NIH-3T3 cells transformed by an activated Ha-ras oncogene. Pulse/chase experiments indicated that RA affects FN biosynthesis rather than its turnover rate. Steady state levels of FN transcripts did not change after treatment of the cells with RA for various times or concentrations, suggesting that RA acts at the translational level. Similar effects were observed in other fibroblasts.

In NIH-3T3 cells, RA had distinct effects on different receptors; it down-modulated retinoic acid receptor (RAR) alpha protein and transcript levels, it up-regulated RARbeta transcripts, and it had no effect on RAR. Transformation of NIH-3T3 cells with an activated Ha-ras oncogene down-modulated RAR expression and abolished responsiveness to RA. We identified the retinoid signal transduction pathways responsible for the effects of RA on FN and RARalpha proteins by the use of the retinoid X receptor-selective compound, SR11237, by stable overexpression of a truncated form of the RARalpha gene, RARalpha403, with strong RAR dominant negative activity, and by overexpression of RARalpha. We conclude that: 1) RA-dependent FN down-modulation is mediated by RARs, 2) retinoid X receptors mediate the observed reduction of RARalpha by RA, and 3) the block of RA responsiveness in Ha-ras cells cannot be overcome by overexpression of RARalpha.

These studies have defined fibronectin and RARalpha as targets of RA in fibroblast cells and have shown that oncogenic transformation renders the cells resistant to RA action.


INTRODUCTION

All-trans- and 9-cis-retinoic acid are the mediators of vitamin A action on growth and differentiation of normal, premalignant, and malignant cells(1, 2) . Their effects are mediated by two classes of nuclear receptors, the RARs (^1)and RXRs, for which they function as respective ligands. Distinct RAR- and RXR-dependent gene pathways exist, and individual receptor subtypes may control distinct gene expression patterns by interacting with RAREs, or RXREs, in the promoter region of different responsive genes(3, 4) . RA has proven effective in differentiation therapy of acute promyelocitic leukemia, a disease characterized by a t(15;17) translocation with breakpoint in the RARalpha gene(5) . In vitro, overexpression of RARalpha has been shown to suppress transformation by v-myb in monoblasts (6) and by polyoma virus in rat fibroblasts(7, 8) . In addition RA treatment of NIH-3T3 cells transformed by the introduction of an activated Ha-ras oncogene inhibited focus formation(9) . Various reports have shown opposing effects of RA and ras on the regulation of the expression of different genes(10, 11, 12, 13) , suggesting that an interaction between the signal transduction pathways mediated by RA and ras may take place. Therefore, studies of this interaction may provide insight into the mechanism whereby RA inhibits transformations.

FN is a large transformation-sensitive glycoprotein composed of two non identical subunits of 220 kDa. It exists in the extracellular matrix and in soluble form in the plasma. Cellular FN is produced in large amounts by fibroblasts and is implicated in a wide range of cellular processes including cell adhesion, migration, morphology, differentiation, and transformation(14, 15) . It is modulated by a variety of effectors including cytokines like transforming growth factor beta and hormones like glucorticoids and RA. Loss of cell surface FN is a hallmark of transformation, and it has been correlated with acquisition of tumorigenic and metastatic potential. This effect has been observed with many oncogenic stimuli, among which are the ras oncogenes(14, 16, 17) .

The ras genes encodes a 21-kDa plasma membrane protein that binds guanine nucleotides and is involved in signal transduction, cell growth, and differentiation(18) . Many types of tumors express mutated forms of the ras protein, resulting in constitutive activation of this protein and altered gene expression(18) .

In this study, we identified fibronectin as target of RA action in NIH-3T3 cells but not in ras-transformed fibroblasts. We also identified retinoid receptors involved in this process.


EXPERIMENTAL PROCEDURES

Cell Culture

NIH-3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% calf serum, 400 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine. Cells were grown to subconfluence and treated with retinoids. Activated Ha-ras-transfected cells were generated and cultured as described(10) . All comparative studies were done with matched pair clones, i.e. all the cells were always transfected with vector plus/minus the activated ras construct. Furthermore identical results were obtained in four NIH-3T3 clones compared to their ras-transformed counterparts. C3H10T1/2 cells were obtained from ATCC (Rockville, MD) and cultured as described(19) . Primary mouse skin fibroblasts were isolated and cultured as described(20) .

Retinoids

RA was obtained from Sigma. The RXR-selective compound, SR11237(21) , was kindly provided by Dr. A. Levin (Hoffman La Roche). RA and SR11237 were dissolved in Me(2)SO at 10 mM and in ethanol at 1 mM, respectively. The maximum concentration of the solvent used was 0.03% for Me(2)SO and 0.1% for ethanol. Subconfluent fibroblasts were incubated in presence of the media containing the required retinoids, and these media were replaced daily. For the last 16 h the cells were serum-starved by adding serum-free media containing 0.1% bovine serum albumin, with or without the effectors.

Metabolic Labeling and Immunoprecipitation

RA- and Me(2)SO-treated cells were washed with PBS and serum-free DMEM containing 0.1% bovine serum albumin, and 10% of the normal level of methionine and cysteine was added. Cells were preincubated for 1 h before adding 80 µCi/ml [S]methionine/cysteine protein labeling mixture (DuPont NEN). After 20 min of incubation, the cell monolayers were washed with cold PBS and lysed with buffer A (40 mM Tris-HCl, pH 8.5, 100 mM NaCl, 2 mM EDTA, 0.5% sodium deoxycholate, 1.0% Nonidet P-40, 0.5% SDS, 2 mM phenylmethylsulfonyl fluoride, and 10 µM leupeptin). Cell lysates were centrifuged at 15,000 times g times 5 min at 4 °C, and the insoluble pellets were discarded. Volumes containing equal amounts of radioactivity (precipitation with 10% trichloroacetic acid) were subjected to immunoprecipitation. Polyclonal rabbit mouse FN antibodies (5 µl) were added. After 2 h of incubation at room temperature, 25 µl of prewashed Pansorbin (Calbiochem, La Jolla, CA) was added and the samples were incubated overnight at 4 °C on a rotary shaker. The immunoprecipitates were washed three times with buffer B (20 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.5% sodium deoxycholate), solubilized in SDS loading buffer, and loaded onto 4-15% polyacrylamide gels(22) .

Pulse/Chase

The reduced level of newly synthesized FN in RA-treated cells may be due to either a reduced rate of biosynthesis or an increased turnover rate. To explore these possibilities we performed pulse/chase experiments. Fibroblasts were pulsed for 20 min with [S]methionine and [S]cysteine and chased with unlabeled amino acids. At the indicated time points, the cells were washed twice with PBS and treated with 10 µg/ml trypsin for 5 min to remove extracellular and cell surface FN. The reaction was stopped by adding 2 mg/ml trypsin inhibitor. The cells were washed with cold PBS containing 2 mM phenylmethylsulfonyl fluoride, lysed in buffer B, and analyzed for labeled FN by immunoprecipitation.

Immunoblot Analysis

To determine intracellular Fn levels, retinoid- and Me(2)SO-treated cells were washed and trypsinized as described in the pulse/chase section. Cells were lysed in Laemmli buffer without reducing agent and bromphenol blue. Lysates were boiled for 5 min and centrifuged to get rid of insoluble cell debris. Protein concentration was determined by the bicinchoninic acid method (23) (Pierce). beta-Mercapthanol and saturated solution bromphenol blue were added to the samples at 1% and 3% final concentrations, respectively. Equal amounts of protein were then loaded onto 4-15% polyacrylamide gels. The proteins were transferred to nitrocellulose (Schleicher & Schuell) on a Bio-Rad electroblot apparatus. The membranes were stained with Ponceau stain. The blots were incubated overnight at 4 °C in 5% milk in TTBS (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20). Rabbit polyclonal mouse FN antibodies (Life Technologies, Inc.) were used at 1:1250 dilution in TTBS, and blots were incubated at room temperature for 1 h. They were rinsed four times with TTBS, and incubated 1 h with horseradish peroxidase-labeled secondary antibodies (anti-rabbit IgG, Amersham Corp.) at 1:5000 dilution in TTBS. The blots were washed five times before determining immunoreactivity by a chemiluminescent method using the ECL Western blotting system (Amersham). Rabbit polyclonal mouse collagen type IV and laminin antibodies were from Becton Dickinson (Bedford, MA).

For the detection of RARalpha and proteins, total SDS lysates were prepared from cells washed twice with ice-cold PBS, as described above, except for the trypsin treatment. Proteins were boiled and run immediately on 10% polyacrylamide gels. They were transferred to nitrocellulose membranes which were then blocked overnight in 5% milk in TBS (50 mM Tris-HCl, 150 mM NaCl). Polyclonal antibodies against the carboxyl termini of RARs from Dr. Chambon's laboratory (24, 25) were diluted 1:1000 in 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 1% bovine serum albumin, and the membranes were incubated at room temperature for 2 h. The blots were rinsed and washed five times in buffer C (50 mM Tris-HCl, 500 mM NaCl, 0.1% Tween 20) and incubated at room temperature for 1 h in 5% nonfat dry milk in PBS containing a 1:3000 dilution of the horseradish peroxidase-labeled IgG. The final wash sequence was three washes with buffer C and two washes with buffer D (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.3% Tween 20)(26) . Blots were developed with ECL.

Stable Transfection

For stable transfection of RARalpha cDNA, the fibroblasts were seeded at 6 times 10^5 cells/100-mm dish 24 h before transfection in regular DMEM medium. Ten µg of the expression plasmid pSG5-RARalphaf (27) and 1 µg of the dominant selective vector pSVneo (28) were cotransfected using the Lipofectamine (Life Technologies, Inc.) methods according to the manufacturer's instructions. Control cells were transfected with 10 µg of pSG5 empty vector and 1 µg of pSVneo vector. G418-resistant colonies were selected in medium containing 1 mg/ml G418, and positive clones (overexpressing RARalpha protein) were isolated and expanded.

Northern Blot Analysis

Isolation of total RNA was performed by using a Total RNA isolation kit (Tel-Test ``b'' Inc., Friendswood, TX). The full-length fragments of the mouse RARs were excised from the expression plasmid pSG5-RAR(29, 30) . The 1.4-kilobase human Fn fragment was obtained from Life Technologies, Inc. The probes were labeled with [P]dCTP using random primer labeling methods. Total RNA (40 µg) was fractionated on a 1% agarose gel and blotted overnight onto Schleicher & Schuell nitrocellulose. The membranes were prehybridized for 2 h at 65 °C in a buffer of 5 times SSC, pH 7.0, 5 times Denhardt's, 0.05 M sodium phosphate, pH 6.8, 0.1% SDS, 5 mM EDTA, 20 µg/ml poly(A)(n), 0.2 mg/ml denatured salmon sperm DNA, and 0.1 mg/ml denatured torula yeast RNA. The probes (2 times 10^6 cpm/ml) were boiled and added to the hybridization buffer (5 times SSC, 1 times Denhardt's solution, 0.02 M sodium phosphate, 5 mM EDTA, 0.2% SDS, 20 µg/ml poly(A)(n), 0.2 mg/ml denatured sperm DNA, and 0.1 mg/ml denatured yeast RNA. The membranes were hybridized for 18 h at 65 °C, followed by two washes with 1 times SSC, 0.1% SDS and two with 0.1 times SSC, 0.15% SDS at 65 °C. Autoradiography on Kodak X-Omat AR film used double intensifying screens. In order to reprobe the membranes with labeled GAPDH, the blots were first stripped in 1% glycerol at 85 °C for 5 min. Densitometric evaluation of Northern blots was performed with NIH Image 1.52 software (created by Wayne Rasband, National Institutes of Health) running on a Macintosh Centris 650 using an XC-77/77CE CCD video camera module.

Infection of NIH-3T3 with Retroviral Vectors

The retroviral vector LRARalpha403SN, in which a truncated RARalpha gene is inserted into the retroviral vector LXSN, was a gift from Dr. S. J. Collins(31, 32) . Cells were seeded at 50% confluence into 100-mm dishes. The next day, they were infected with the LXSN and LXRARalphaSN retroviral vector in presence of 4 µg/ml Polybrene(31) . After overnight incubation, the medium was replaced and cells were grown for 36-48 h before G418 (1 mg/ml) was added. G418-resistant cells were isolated.

Transient Transfection with Constructs Containing beta-RARE-tk-LUC

beta-RARE-tk-LUC was a gift from Dr. S. Minucci (National Institutes of Health)(33) . Fibroblasts (1.5 times 10^5/dish) were seeded in 35-mm dishes. After 24 h, cells were cotransfected with 1 µg of the beta-RARE-tk-LUC and 1 µg of the cytomegalovirus-beta-galactosidase reporter (34) using Lipofectamine reagent. Six hours post-transfection, the cells were incubated in DMEM containing 10% serum for 16 h. The cells were treated with 2 µM RA or solvent (Me(2)SO) for 24 h. Cells were lysed with reporter lysis buffer (Promega, Madison, WI). Luciferase activity was determined in 1 µg of protein from each sample using the luciferase assay system from Promega in a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA). beta-Galactosidase activity was quantified by the FluoReporter LacZ/Galactosidase kit (Molecular Probes, Inc., Eugene, OR).


RESULTS

Inhibition of FN Biosynthesis by RA in NIH-3T3 but Not in Ha-ras NIH-3T3 Cells

FN levels were markedly reduced by RA in pSVneo, but not in Ha-ras-transfected cells (Fig. 1A). The effect was specific for FN, since neither collagen type IV nor laminin B1 and B2 chains (the only ones to be detected in NIH-3T3 cells) were affected. RA inhibition of FN was time-dependent (Fig. 1B) and concentration-dependent (Fig. 1C). A 3-fold reduction of intracellular FN was already observed after 12 h of treatment (Fig. 1B). RA caused a 90% down-regulation at 2 times 10M.


Figure 1: Regulation of intracellular FN protein levels by RA in pSVneo and Ha-ras NIH-3T3 cells. A, subconfluent cultures were treated for 24 h with 2 µM RA. Cell monolayers were trypsinized to remove extracellular and cell surface-associated proteins and lysed. Lysates were examined by immunoblot analysis using specific polyclonal antibodies as under ``Experimental Procedures.'' B, subconfluent fibroblasts were treated with 2 µM RA and examined for intracellular FN. C, fibroblasts were treated for 48 h with the indicated concentrations of RA. Intracellular FN was determined as described above.



Mechanism of RA Inhibition of Newly Synthesized FN

RA-treated cells were metabolically labeled with a mixture of [S]methionine/cysteine for 20 min, lysed, and immunoprecipitated with specific anti-FN antibodies. The choice of the labeling time was crucial because FN takes about 30 min to reach the cell surface from the cytosolic site of synthesis (data not shown and (35) ). RA inhibited the newly synthesized FN in a time-dependent fashion. An 80% reduction was observed after 4 h of RA treatment (Fig. 2A).


Figure 2: Effect of RA on newly synthesized, labeled FN in NIH-3T3 cells. A, subconfluent fibroblasts on 35-mm dishes were treated with 2 µM RA for the indicated times. Cells were pulsed with 80 µCi/ml [S]methionine/cysteine protein labeling mixture, and cell lysates were analyzed by immunoprecipitation as described under ``Experimental Procedures.'' B, effect of RA on the turnover rate of intracellular FN. Cells were treated with 2 mM RA for 3 h, pulsed with 100 µCi/ml [S]methionine/cysteine protein labeling mixture, and chased for the indicated times with unlabeled amino acids. The levels of intracellular labeled FN were determined by immunoprecipitation as described under ``Experimental Procedures.'' The experiment shown is representative of four experiments.



In pulse/chase experiments, the rate of disappearance of labeled FN was not altered by RA treatment of the cells (Fig. 2B). The time required to reduce the amount of S-FN by 50% was 28 ± 2 and 31 ± 3 min in RA- and Me(2)SO-treated cells, respectively. Therefore, a reduction of FN biosynthetic rate likely accounts for the effects of RA.

Northern blots of total cellular RNA from RA-treated and control cells were hybridized to FN and GAPDH probes. The FN mRNA band intensities, which represent relative steady-state level, were normalized to GAPDH mRNA band intensities. The results (Fig. 3) reveal that the accumulated levels of FN mRNA were not altered either by different RA concentration or by times of RA treatment. RA failed to alter FN mRNA in Ha-ras NIH-3T3 cells.


Figure 3: Effect of RA on FN mRNA levels in pSVneo and Ha-ras NIH-3T3 cells. Subconfluent cultures were treated with 2 µM RA for 48 h (upper panels) or with the indicated RA concentrations for 48 h (lower left panel) or with 2 µM RA for the indicated times. Total RNA was fractionated, transferred onto nitrocellulose, and hybridized to P-labeled probes for FN and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The sizes of the detected mRNA were 9.1 and 1.6 kilobases for FN and GAPDH.



RA Modulation of RARs in pSVneo NIH-3T3 but Not in Ha-ras NIH-3T3 Cells

In pSVneo NIH-3T3 cells, RARalpha transcripts were constitutively expressed and slightly (30%) down-regulated by RA (data not shown). RAR mRNAs were expressed to a lower extent than RARalpha mRNAs and were not substantially altered by RA. RARbeta transcripts were induced in pSVneo cells to a similar extent (data not shown) as in primary mouse skin fibroblasts(36) . In Ha-ras NIH-3T3 cells, the levels of RARs mRNA were generally lower than in control cells and were not responsive to RA treatment.

RARalpha protein levels were strongly down-regulated by RA in NIH-3T3 cells, but not in Ha-ras cells (Fig. 4A). RAR proteins were not altered by RA in either type of cells and could be detected only after overexposing the blots (data not shown). We were unable to detect RARbeta proteins. The effect of RA on the levels of RARalpha protein was time- and dose-dependent (Fig. 4B). A concentration of 0.1 nM RA was sufficient to bring about a 80% inhibition of RARalpha protein, and a 40% inhibition could be already observed after 2 h of RA treatment.


Figure 4: Effect of RA on the expression of RARs in pSVneo and Ha-ras NIH-3T3 cells. A, effect of RA on the expression of RARalpha protein levels. Subconfluent fibroblasts were treated for 24 h with 3 µM RA. Total cellular protein extracts were examined by immunoblot analysis using RARalpha mouse polyclonal antibodies as described under ``Experimental Procedures.'' A 2-h exposure detected RAR protein levels (data not shown) as compared to 1 min for RARalpha. B, time- and concentration-dependent effect of RA on the expression of RARalpha proteins. Subconfluent fibroblasts were treated for 24 h with RA (left panel) or for different times with 3 µM RA (right panel). Total cell proteins were analyzed for RARalpha content by immunoblotting techniques as described above.



RA Inhibition of FN and RARalpha Proteins in Fibroblast Cells

We investigated the effects of RA on FN and RARalpha proteins in C3H10T1/2 mouse embryo fibroblasts and in primary mouse skin fibroblasts. RA markedly reduced the level of FN and RARalpha in these two cells (Fig. 5).


Figure 5: FN inhibition by RA in fibroblasts. NIH-3T3, C3H10T1/2, and primary mouse skin fibroblast cells were treated with 3 µM RA for 24 h. RARalpha proteins were determined by immunoblotting analysis as described in Fig. 4A. Intracellular FN was determined by immunoprecipitation analysis as in Fig. 2A.



Role of RAR Signal Transduction Pathways on RA Inhibition of FN and RARalpha Proteins

SR11237, an RXR-selective compound, specifically activates reporter genes fused to the RXR-responsive element of the CRBPII promoter, to which only RXR-RXR homodimers bind, and is unable to induce genes driven by an RAR-responsive element, like the RARE of RARbeta and CRBPI(21) . The RAR-mediated signaling pathways can be blocked by overexpressing a mutated form of the RARalpha gene, RARalpha403, which shows strong dominant negative activity(31, 32) . The truncated form of the RARalpha gene, RARalpha403, inserted into the retroviral vector LXRARalphaSN and the corresponding control retrovirus LXSN were used. We infected NIH-3T3 cells with these amphotrophic retroviruses containing the neomycin resistance gene. Neomycin-resistant cells were isolated and expanded. Northern blot analysis was performed to detect the expression of the typical 4.7-kilobase retroviral transcripts containing the RARalpha403 mRNA (Fig. 6). The dominant negative activity of such mutated receptor was confirmed in RARalpha403 NIH-3T3 cells by transient reporter assays. LXSN control and LXRARalpha403SN NIH-3T3 cells were transiently transfected with a vector carrying the luciferase reporter gene fused to two copies of the RARE of RARbeta2 gene(33) , RA-dependent transactivation of luciferase was then evaluated. Cells overexpressing RARa403 transcripts showed an almost negligible 1.2-fold induction of luciferase activity in comparison to a 5-fold induction in control LXSN cells (Fig. 6B). Similar data were obtained by others in tkNIH-3T3 cells infected with the very same retroviral vectors(31) .


Figure 6: Suppression of RA-induced transactivation in NIH-3T3 cells by overexpression of the RAR dominant negative mutant, RARalpha403. A, RARalpha403 expression in LXRARalpha403SN-infected cells. Total RNA from LXSN- and LXRARalpha403SN-infected cells treated with 3 µM RA for 24 h were examined by Northern blot analysis using labeled RARalpha probes. B, effect of RA on the transactivation of the beta-RARE-tk-LUC construct in LXSN- and LXRARalpha403SN-infected cells. After transfection, cells were treated with 3 µM RA for 24 h and assayed for luciferase activities as described under ``Experimental Procedures.'' Results are representative of four separate experiments. Relative luciferase activity is the rate of activity in RA- versus Me(2)SO-treated cells (after correcting for transfection efficiency) in LXSN- and LXRARalpha403SN-infected cells. 1, uninfected cells; 2, LXSN-infected cells; 3, LXRARalpha403SN-infected cells.



RA failed to down-regulate the intracellular FN levels in the LXRARalpha403SN cells (Fig. 7B, left panel). Furthermore, the RXR-selective compound, SR11237, also failed to reduce FN protein (Fig. 7B, right panel). These results indicate that an RAR-mediated signaling pathway likely accounts for the RA-dependent FN down-regulation.


Figure 7: Role of RARs in RA inhibition of RARalpha and FN proteins. A, left panel, effect of RA on RARalpha protein levels in LXSN and LXRARalpha403SN-infected cells. Subconfluent cells were treated with 3 µM RA for 24 h. Total cell extracts were analyzed by immunoblotting for RARalpha protein. Right panel, effect of SR11237 on the levels of RARalpha in NIH-3T3 cells. Cells were treated with 2 µM RA, 1 µM SR11237, or the solvents (control) for 24 h before determining the levels of RARalpha. B, right panel, effect of RA on intracellular FN in LXSN and LXRARalpha403SN-infected cells. Subconfluent cultures were treated with 2 µM RA for 48 h and intracellular FN was determined as in Fig. 2A. Left panel, effect of SR11237 on intracellular FN in NIH-3T3 cells. Fibroblasts were exposed to 2 µM RA, 1 µM SR11237, or the solvents (control) for 48 h, and intracellular FN was determined as above.



Similar experiments were performed, looking at the RA modulation of RARalpha (Fig. 7A). In LXRARalphaSN NIH-3T3, treatment with RA caused a marked reduction of the levels of RARalpha, ruling out the involvement of RAR signal transduction pathways. This finding was strengthened by the inhibition of RARalpha in cells treated with SR11237 to a similar extent as that achieved by RA treatment (Fig. 7A, right panel). This suggests the involvement of RXR in this effect.

Effect of RA in NIH-3T3 Cells Overexpressing RARalpha

To further investigate the role of RARs, we generated cell lines overexpressing the RARalpha gene. Cotransfections of NIH-3T3 cells with the plasmid pSVneo, harboring the neomycin resistance gene, and the pSG5RARaf vector, containing the full-length RARalpha gene, were performed. G418-resistant clones were isolated, expanded, and tested for RARalpha protein overexpression. Two representative clones are shown in Fig. 8. Both express very high levels of RARalpha protein, however, the levels of RARalpha were down-modulated by RA only in clone 3A. Along the same trend, when FN sensitivity to RA was determined, RA failed to reduce the level of FN in the resistant clone.


Figure 8: Effect of RA on FN synthesis in NIH-3T3 cells overexpressing RARalpha. Cells were co-transfected with pSG5RARalphaf and pSVneo plasmids. Neomycin-resistant clones, 13A and 3A, overexpressing RARalpha proteins were treated with 3 µM RA for 48 h. RARalpha protein levels and intracellular FN were determined by immunoblot and immunoprecipitation analysis, respectively, as described under ``Experimental Procedures.''



Effect of RA on Ha-ras NIH-3T3 Cells Overexpressing RARalpha and RARalpha403

A similar series of experiments was performed in Ha-ras NIH-3T3 cells. Since the levels of RARs were generally lower than in control cells, we generated Ha-ras NIH-3T3 cell lines, which overexpressed RARalpha. The RA effects on FN biosynthesis were evaluated. Overexpression of RARalpha protein was not sufficient to overcome the block on RA responsiveness (Fig. 9A). Similarly, disruption of the RAR signaling pathways by the introduction of the dominant negative RAR construct, RARalpha403, into Ha-ras NIH-3T3 cells, was ineffective in altering the responsiveness of FN protein to RA.


Figure 9: Effect of RA on FN in Ha-ras NIH-3T3 overexpressing lXRARalpha403SN or RARalpha. A, cells were transfected with pSG5RARalphaf and pSVneo plasmids. Neomycin-resistant colonies were isolated and treated with 2 µM RA for 48 h. RARalpha protein (upper panel) and intracellular FN (lower panel) levels were determined as described in Fig. 8. B, upper panel, RARalpha403 expression in LXRARalpha403SN-infected cells. Total RNA from LXSN- and LXRARalpha403SN-infected cells was analyzed by Northern blot with radiolabeled RARalpha probes. Lower panel, effect of RA on intracellular FN in LXSN- and LXRARalpha403SN-infected cells. Subconfluent fibroblasts were treated with 3 µM RA for 48 h, and intracellular FN was determined as in Fig. 2A.




DISCUSSION

We have identified FN as a molecule whose biosynthesis is down-regulated by RA in normal, but not in Ha-ras-transformed NIH-3T3 cells. The inhibition of FN biosynthesis by RA is specific, as neither collagen type IV nor laminin were affected by RA, and is RA dose- and time-dependent. Two lines of evidence suggest that RA acts on FN at a post-transcriptional level. First, the rate of newly synthesized intracellular FN is reduced by RA treatment, an event not due to an increased FN turnover rate. Second, RA did not alter the levels of FN transcripts, consistent with the absence of RARE or RXRE in the promoter region of the FN gene(37, 38) . Effects of RA in other cell systems have been reported. FN mRNA and protein levels were increased in primary hepatocytes from vitamin A-deficient rats, while RA treatment caused a reduction of FN mRNA and protein levels(39) . In C3H10T1/2 fibroblast cells, a complex RA-dependent regulation of FN was observed as the cell surface levels increased, while intracellular FN and FN mRNA decreased after RA(19) .

RA generally controls gene expression at the transcriptional level. However, lipoprotein lipase enzyme expression in 3T3-L1 adipocytes was down-regulated, but mRNA levels were not affected by RA treatment (40) . RA induction of differentiation of F9 cells is achieved by controlling the expression of various genes. Early responsive genes are thought to be transcriptionally regulated, while late responsive genes may be controlled both at the transcriptional and post-transcriptional levels(41) . Laminin biosynthesis is switched on, while synthesis and secretion of FN is switched off by RA treatment of F9 cells (42, 43, 44) .

Transformation of NIH-3T3 cells with an activated ras caused RARalpha and to be expressed to lower levels than in normal cells, while RA induction of RARbeta was absent. In addition to specific mutations in the RARalpha gene(5) , alteration of the expression of RARs by transformation or in tumor derived cells has been reported. In lung cancer cells, RARalpha and and RXRs were well expressed; however, RA induction of RARbeta was not observed(45) . Estrogen receptor-negative human breast cancer cells were insensitive to RA inhibition of cell growth, probably due to a low level of RARalpha expression(46) . Primary keratinocytes infected by v-ras showed lower levels of RARalpha and proteins, which is accompanied by a reduction in RA- induction of reporter genes fused to a RARE. (^2)The molecular mechanism of this down-regulation is not known yet, but it could have important implications in explaining the variability in RA responsiveness of different tumor cells.

RARalpha protein is down-modulated by RA in a dose- and time-dependent fashion in NIH-3T3 cells. The modest inhibition (30%) of RARalpha mRNA is in agreement with various reports in different cell lines and tissues, which, however, had exclusively focused on the effect of RA at the level of transcripts (36, 47, 48) . More recently, RA-dependent down-modulation of RARalpha proteins was reported in estrogen receptor-positive human breast cancer cells(46) . Transcriptional regulation of retinoid receptors by RA has long been known, and one of the first RARE was found in the promoter region of the RARbeta gene(49) .

This work also shows that the RA-dependent down-modulation of intracellular FN appears to be RAR-mediated. The introduction of a mutated RARalpha gene, which has strong dominant negative activity and blocks the RAR-mediated signaling pathways, abolished the RA inhibition of FN. Furthermore the RXR-selective compound, SR11237, was unable to mimic the action of RA on the intracellular FN. We conclude that RARalpha down-modulation by RA is likely mediated by RXRs, since RA reduces RARalpha levels, even when we blocked RAR-mediated signaling pathways by the overexpression of the RAR dominant negative gene, RARalpha403. In addition the RXR-selective retinoid, SR11237, is as powerful as RA in down-regulating RARalpha protein.

In our RARalpha overexpression studies we isolated a clone, 13A, which appeared to be insensitive to RA in that the two gene products, FN and RARalpha, were not responsive to RA. The mechanism of the observed RA resistance is not clear. We showed that action of RA on FN is mediated by RAR and is dependent on RXR/RAR heterodimer, while RARalpha inhibition by RA is likely mediated by RXR/RXR homodimer. The fact that RA resistance is observed for both gene products argues against a defect localized entirely on the RAR signaling pathway. If this were the case, RARalpha protein expression should have remained sensitive to RA effects. Introduction of an activated ras alters the responsiveness to RA and the level of expression of RARs. Manipulation of RAR protein levels was utilized in an attempt to correlate these two observations.

Overexpression of the RARalpha gene in Ha-ras NIH-3T3 cells was not sufficient to overcome the block in FN and RARalpha (data not shown) responsiveness. Failure to regain RA sensitivity after constitutively expressing RARbeta in lung cancer cells has been reported (45) . RA-dependent induction of a luciferase reporter gene fused to the RARE of the RARbeta promoter was equally or more efficient in Ha-ras NIH-3T3 than in normal cells (data not shown). Caution should be used in evaluating the physiological relevance of reporter gene assays, because the RARE is taken out of the context of its natural promoter. Swisshelm et al.(50) showed that when a 1.5-kilobase region of the RARbeta2 promoter was used in reporter gene constructs, instead of the RARE, suppression of RA-induced activation was detected in human MCF-7 breast cancer cells. The observation that beta-RARE-tk-LUC can be activated in Ha-ras NIH-3T3 cells suggests that necessary factors for activating betaRARE are functional. The level of retinoid receptor expression often does not correlate with RA-responsiveness. RARalpha was expressed in most leukemia cells whether or not they were responsive to RA(51, 52, 53) . In melanomas, the level of RARbeta and RAR were similar in RA-sensitive and -resistant cells (54) . These findings and the observed failure of RARalpha overexpression to confer RA responsiveness to Ha-ras cells suggests that other factors are required to mediate RA action. These factors may be missing or not functional after ras transformation.


FOOTNOTES

(^1)
The abbreviations used are: RAR, retinoic acid receptor; RA, retinoic acid; FN, fibronectin; RARE, RAR response element; RXR, retinoid X receptor; RXRE, RXR response element; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline.

(^2)
G. Scita, N. Darwiche, E. Greenwald, M. Rosenberg, K. Politi, and L. M. De Luca, manuscript in preparation.

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: NCI/NIH, Bldg. 37, Rm. 3A17, 37 Convent Dr., MSC 4255, Bethesda, MD 20892-4255. Tel.: 301-496-2698; Fax: 301-496-8709.


ACKNOWLEDGEMENTS

We thank Dr. Steven J. Collins for the retroviral construct LRARalpha403SN and for reviewing the manuscript prior to submission. We are also indebted to Drs. Keiko Ozato and Saverio Minucci for their gift of constructs containing the beta-RARE-tk-luciferase reporter gene. We thank Dr. Pierre Chambon for the pSG5-RAR construct and the mouse-polyclonal RAR antibodies.


REFERENCES

  1. De Luca, L. M. (1991) FASEB J. 5, 2924-2933 [Abstract/Free Full Text]
  2. Lotan, R. (1980) Biochim. Biophys. Acta 605, 33-91 [CrossRef][Medline] [Order article via Infotrieve]
  3. Pemrick, S. M., Lucas, D. A., and Grippo, J. F. (1994) Leukemia 8, S1-S10 [Medline] [Order article via Infotrieve]
  4. Chambon, P. (1994) Cell Biol. 5, 115-125
  5. Bollag, W., and Holdener, E. E. (1992) Ann. Oncol. 3, 513-526 [Abstract]
  6. Smarda, J., Sugarman, J., Glass, C., and Lipsick, J. (1995) Mol. Cell. Biol. 15, 2474-2481 [Abstract]
  7. Talmage, D. A., and Lackey, R. S. (1992) Oncogene 7, 1837-1845 [Medline] [Order article via Infotrieve]
  8. Talmage, D. A., and Listerud, M. (1994) Oncogene 9, 3557-3563 [Medline] [Order article via Infotrieve]
  9. Cox, L. R., Motz, J., Troll, W., and Garte, S. J. (1991) J. Cancer Res Clin. Oncol. 117, 102-108 [Medline] [Order article via Infotrieve]
  10. Kosa, K., and De Luca, L. M. (1993) Biochem. Biophys. Res. Commun. 196, 1025-1033 [CrossRef][Medline] [Order article via Infotrieve]
  11. Gopas, J., Ehrlich, T., Cohen, O., Wishniak, O., Tainsky, M. A., Segal, S., Rager-Zisman, B., and Isakov, N. (1992) Int. J. Cancer 52, 329-335 [Medline] [Order article via Infotrieve]
  12. Kreider, B. L., and Rovera, G. (1992) Oncogene 7, 135-140 [Medline] [Order article via Infotrieve]
  13. Buettner, R., Yim, S. O., Hong, Y. S., Boncinelli, E., and Tainsky, M. A. (1991) Mol. Cell. Biol. 11, 3573-3583 [Medline] [Order article via Infotrieve]
  14. Hynes, R. O. (1990) Fibronectin , Springer Verlag, New York
  15. Hynes, R. O., and Yamada, K. M. (1982) J. Cell Biol. 95, 369-377 [Medline] [Order article via Infotrieve]
  16. Chandler, L. A., and Bourgeois, S. (1991) Cell Growth & Diff. 2, 379-384
  17. Chandler, L. A., Ehretsmann, C. P., and Bourgeois, S. (1994) Mol. Cell. Biol. 14, 3085-3093 [Abstract]
  18. Bollag, G., and McCormick, F. (1991) Annu. Rev. Cell Biol. 7, 601-632 [CrossRef]
  19. Scita, G., and Wolf, G. (1994) Carcinogenesis 15, 1043-1048 [Abstract]
  20. Hennings, H., Michael, D., Cheng, C., Steinert, P., Holbrook, K., and Yuspa, S. H. (1980) Cell 19, 245-254 [Medline] [Order article via Infotrieve]
  21. Lehmann, J. M., Jong, L., Fanjul, A., Cameron, J. F., Lu, X. P., Haefner, P., Dawson, M. I., and Pfahl, M. (1992) Science 258, 1944-1946 [Medline] [Order article via Infotrieve]
  22. Scita, G., and Wolf, G. (1994) Biochim. Biophys. Acta 1223, 29-35 [Medline] [Order article via Infotrieve]
  23. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76-85 [Medline] [Order article via Infotrieve]
  24. Gaub, M. P., Rochette-Egly, C., Lutz, Y., Ali, S., Matthes, H., Scheuer, I., and Chambon, P. (1992) Exp. Cell Res. 201, 335-346 [Medline] [Order article via Infotrieve]
  25. Rochette-Egly, C., Lutz, Y., Saunders, M., Scheuer, I., Gaub, M. P., and Chambon, P. (1991) J. Cell Biol. 115, 535-545 [Abstract]
  26. Ali, M., Torian, B. E., and Vedeckis, W. V. (1992) Biochem. Biophys. Res. Commun. 182, 1032-1039 [Medline] [Order article via Infotrieve]
  27. Brand, N. J., Petkovich, M., and Chambon, P. (1990) Nucleic Acids Res. 18, 6799-6806 [Abstract]
  28. Southern, P. J., and Berg, P. (1982) J. Mol. Appl. Genet. 1, 327-341 [Medline] [Order article via Infotrieve]
  29. Zelent, A., Krust, A., Petkovich, M., Kastner, P., and Chambon, P. (1989) Nature 339, 714-717 [CrossRef][Medline] [Order article via Infotrieve]
  30. Petkovich, M., Brand, N. J., Krust, A., and Chambon, P. (1987) Nature 330, 444-450 [CrossRef][Medline] [Order article via Infotrieve]
  31. Tsai, S., Bartelmez, S., Heyman, R., Damm, K., Evans, R., and Collins, S. J. (1992) Genes & Dev. 6, 2258-2269
  32. Damm, K., Heyman, R. A., Umesono, K., and Evans, R. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2989-2993 [Abstract]
  33. Minucci, S., Zand, D. J., Dey, A., Marks, M. S., Nagata, T., Grippo, J. F., and Ozato, K. (1994) Mol. Cell. Biol. 14, 360-372 [Abstract]
  34. MacGregor, G. R., and Caskey, C. T. (1989) Nucleic Acids Res. 17, 2365 [Medline] [Order article via Infotrieve]
  35. Olden, K., and Yamada, K. M. (1977) Cell 11, 957-969 [Medline] [Order article via Infotrieve]
  36. Tsou, H. C., Lee, X., Si, S. P., and Peacocke, M. (1994) Exp. Cell Res. 211, 74-81 [CrossRef][Medline] [Order article via Infotrieve]
  37. Dean, D. C., Bowlus, C. L., and Bourgeois, S. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 1876-1880 [Abstract]
  38. Nakajima, T., Nakamura, T., Tsunoda, S., Nakada, S., and Oda, K. (1992) Mol. Cell. Biol. 12, 2837-2846 [Abstract]
  39. Kim, H. Y., and Wolf, G. (1987) J. Biol. Chem. 262, 365-371 [Abstract/Free Full Text]
  40. Kamei, Y., Kawada, T., Fujita, A., Etinne, J., Noe, L., and Sugimoto, E. (1992) Biochem. Int. 26, 923-934 [Medline] [Order article via Infotrieve]
  41. Gudas, L. J. (1990) Methods Enzymol. 190, 131-140 [Medline] [Order article via Infotrieve]
  42. Cooper, A. R., Taylor, A., and Hogan, B. L. (1983) Dev. Biol. 99, 510-516 [Medline] [Order article via Infotrieve]
  43. Strickland, S., Smith, K. K., and Marotti, K. R. (1980) Cell 21, 347-355 [Medline] [Order article via Infotrieve]
  44. Kleinman, H. K., Ebihara, I., Killen, P. D., Sasaki, M., Cannon, F. B., Yamada, Y., and Martin, G. R. (1987) Dev. Biol. 122, 373-378 [Medline] [Order article via Infotrieve]
  45. Zhang, X. K., Liu, Y., Lee, M. O., and Pfahl, M. (1994) Cancer Res. 54, 5663-5669 [Abstract]
  46. van de Leede, B. M., Folkers, G. E., van den Brink, C. E., van der Saag, P. T., and van der Burg, B. (1995) Mol. Cell. Endocrinol. 109, 77-86 [CrossRef][Medline] [Order article via Infotrieve]
  47. Hu, L., and Gudas, L. J. (1990) Mol. Cell. Biol. 10, 391-396 [Medline] [Order article via Infotrieve]
  48. The, H. D., Marchio, A., Tiollais, P., and Dejean, A. (1995) EMBO J. 8, 429-433 [Abstract]
  49. de The, H., Vivanco-Ruiz, M., Tiollais, P., Stunnenberg, H., and Dejean, A. (1990) Nature 343, 177-180 [CrossRef][Medline] [Order article via Infotrieve]
  50. Swisshelm, K., Ryan, K., Lee, X., Tsou, H. C., Peacocke, M., and Sagar, R. (1995) Cell Growth & Diff. 5, 133-143
  51. Gallagher, R. E., Said, F., Pua, I., Papenhausen, P. R., Paietta, E., and Wiernik, P. H. (1989) Leukemia 3, 789-795 [Medline] [Order article via Infotrieve]
  52. Largment, C., Detmer, K., Corral, J. C., Hack, F. M., and Lawrence, H. J. (1989) Blood 74, 99-102 [Abstract]
  53. Wang, C., Curtis, J. E., Minden, M. D., and McCulloch, E. A. (1989) Leukemia 3, 264-269 [Medline] [Order article via Infotrieve]
  54. Clifford, J. L., Petkovich, M., Chambon, P., and Lotan, R. (1990) Mol. Endocrinol. 4, 1546-1555 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.